Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Novo Nordisk A/S ADR (NY: NVO )

105.26 +0.20 (+0.19%)
Streaming Delayed Price Updated: 10:05 AM EST, Nov 25, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Novo Nordisk A/S ADR

< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
7 Reliable Blue-Chip Stocks That Cannot Miss
These reliable blue-chip stocks to own are the closest thing to slam dunk investments that exist. Discover why you should buy them now. 
Via InvestorPlace
Eli Lilly Secures China Nod For Popular Weight Loss/Diabetes Drug Tirzepatide
Eli Lilly's diabetes drug tirzepatide receives approval in China, intensifying competition with Novo Nordisk's Ozempic. This move signals a significant expansion in the Asian market, where GLP-1... 
Via Benzinga
HIMS Stock Alert: Hims & Hers Shares Rocket on Weight Loss Injections
HIMS stock is catching a bid after Hims & Hers announced that it would begin providing access to GLP-1 weight-loss injections. 
Via InvestorPlace
7 Biotech Stocks That Could Breathe New Life Into Your Portfolio
Thanks to the underlying pertinence, these established biotech stocks to buy offer confidence to investors facing tricky market conditions. 
Via InvestorPlace
Wellness Platform Hims & Hers Health Adds GLP-1 Injections For Weight Loss, Stock Soars
Hims & Hers Health expands its weight loss offerings with GLP-1 injections and oral medication kits. Pricing starts at $79/month. 
Via Benzinga
Is Novo Nordisk Stock a Millionaire Maker?
Novo Nordisk's stock may look expensive today, but that may not be the case in even a year or two. 
Via The Motley Fool
Smart Money Is Betting Big In NVO Options
Via Benzinga
Here's How Much You Would Have Made Owning Novo Nordisk Stock In The Last 10 Years
Via Benzinga
Genetic Profile Key To Novo Nordisk's Wegovy's Weight-Loss Effectiveness, Study Reveals
Certain genes may predict strong responses to Novo Nordisk's Wegovy (semaglutide) in obesity treatment, with patients showing significant weight loss linked to a "hungry gut" genetic profile. This... 
Via Benzinga
Magnificent Seven? Just Two Members Meet This Earnings Criteria
These megacaps meet triple-25% growth standards. 
Via Investor's Business Daily
Microsoft Leads Five Stocks Near Buy Points As Market Flashes Green
The market has flashed a green signal to investors. 
Via Investor's Business Daily
EXCLUSIVE: GameStop, AMC Buzz 'May Prove To Be Short-Lived,' CEO Of Company Behind MEME ETF Tells Benzinga
The company behind the MEME ETF shares what it would take to bring the meme stock fund back to the market. 
Via Benzinga
Topics ETFs
Should Quality Investors Include NYSE:NVO in Their Portfolio?
Is NOVO-NORDISK A/S-SPONS ADR (NYSE:NVO) suited for quality investing? 
Via Chartmill
Spotlight on Novo Nordisk: Analyzing the Surge in Options Activity
Via Benzinga
Pharma Stocks Outlook: Where Are 2024’s Top Performers Headed Next?
Investors want to know where 2024's top-performing pharma stocks are headed in the second half of the year for good reason. 
Via InvestorPlace
10 Health Care Stocks Whale Activity In Today's Session
Via Benzinga
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries
Elevai Labs (NASDAQ: ELAB) Acquires Rights To Develop Muscle Loss Prevention Assets For Anticipated Use In Anti-Obesity Treatments, Launches Two New Subsidiaries 
Via News Direct
Meet the GLP-1 Drug That Could Be the Biggest Concern for Eli Lilly and Novo Nordisk
Could Amgen be the next stock to soar due to a GLP-1 drug? 
Via The Motley Fool
7 Pharma Stocks Harnessing AI Brainpower for Big Breakthroughs
AI continues to impact pharma stocks to buy in a major way, with these shares particularly well positioned as things heat up. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
Patent Peril: 3 Stocks at Risk From the FTC’s Drug Crusade
The FTC is putting these three drug stocks at risk by trying to strip their therapies of protection from generics. 
Via InvestorPlace
Topics Intellectual Property
Exposures Intellectual Property
No Wegovy Shortage in Denmark Amid High Demand, Novo Nordisk Confirms
Novo Nordisk confirms there is no anticipated shortage of Wegovy in Denmark, despite prior warnings from the Danish Medicines Agency about limited supplies. The company addresses high demand and... 
Via Benzinga
If You'd Invested $1,000 in Novo Nordisk Stock 5 Years Ago, Here's How Much You'd Have Today
Back then, the company wasn't very well known to U.S. investors. That's absolutely not the case these days. 
Via The Motley Fool
Eli Lilly Strikes Deal To Combat Counterfeit Diabetes And Weight Loss Drugs Mounjaro And Zepbound
Eli Lilly has settled with Totality Medispa over counterfeit Mounjaro and Zepbound sales. The spa will pay damages and cease using Lilly branding. Corrective measures include compliance with federal... 
Via Benzinga
Novo Nordisk Bets Up to $600 Million on Ozempic 2.0. Here's Why the Stock Is a Buy.
This company is serious about maintaining its leadership. 
Via The Motley Fool
2 Top Pharma Stocks That Just Keep Getting Better and Better
Both of these businesses are finding traction in a pair of major markets. 
Via The Motley Fool
Novo Nordisk's Wegovy Delivers: Long-Term Study Shows Sustained Weight Loss As Drugmaker Tries To Woo Insurers And Governments
The data could potentially bolster Novo's case for Wegovy as it attempts to convince insurers and governments to cover the cost of the drug. 
Via Benzinga
Novo Nordisk's Hemophilia Candidate Can Prevent Bleeding Episodes Effectively, Regardless Of Dosing Frequency
Novo Nordisk's Phase 3a trial demonstrates a significant reduction in bleeding episodes with Mim8 treatment for hemophilia A patients. Superior efficacy and safety profile revealed. 
Via Benzinga
How Viking Therapeutics Stock Could 30x
This mid-cap biopharma may one day be a titan of the industry. 
Via The Motley Fool
The Must-Watch List: 3 Stocks to Snap Up as Soon as They Hit Bargain Territory
These three companies could soon be the next bargain stocks to buy as the market adjusts to their developing situations. 
Via InvestorPlace
Billionaire Jim Simons Owns These 2 Healthcare Stocks: Should You?
These stocks are both experts in their respective fields. 
Via The Motley Fool
< Previous 1 2
...
15 16 17 18 19 20 21 22 23
...
65 66 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.